UK markets close in 3 hours 39 minutes
  • FTSE 100

    +19.65 (+0.26%)
  • FTSE 250

    +2.55 (+0.01%)
  • AIM

    -0.82 (-0.10%)

    +0.0031 (+0.28%)

    -0.0012 (-0.10%)
  • Bitcoin GBP

    -583.86 (-2.52%)
  • CMC Crypto 200

    -8.16 (-1.32%)
  • S&P 500

    +23.02 (+0.57%)
  • DOW

    +141.43 (+0.43%)

    +0.47 (+0.63%)

    +0.90 (+0.05%)
  • NIKKEI 225

    +258.55 (+0.93%)

    +90.98 (+0.45%)
  • DAX

    +72.86 (+0.47%)
  • CAC 40

    +41.89 (+0.58%)

Netherlands Diabetes Market Report 2023 to 2028: Industry Trends, Growth, Impact of Inflation and Opportunity Company Analysis

Company Logo
Company Logo

Dutch Diabetes Market

Dutch Diabetes Market
Dutch Diabetes Market

Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Netherlands Diabetes Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to's offering.

The Netherlands Diabetes Market will reach US$ 3.36 Billion in 2028 according to the publisher.

Diabetes is a chronic, life-threatening disease with no available cure. According to IDF Europe, there are more than 60 million diabetic people in the European Region; by 2045, this number will rise by 13%. In the Netherlands, the prevalence of diabetes mellitus (DM) is increasing rapidly. Netherlands' care for diabetes mainly concentrates on primary health care, with responsibility for most aspects of care in the hands of general practitioners.

Generally, primary health care in The Netherlands provides a good standard of care for subjects with diabetes mellitus. Another point of concern is the rise in the prevalence of obesity, leading to a vast increase in subjects with metabolic syndrome. Therefore, DM (diabetes mellitus) care and its provision will play an essential role in health care in The Netherlands.

Type 2 Diabetes will grow due to the rise in the Prevalence of Obesity

The Netherlands has observed a rise in the prevalence of type 2 diabetes during the last decade. This rise is due to the aging of Dutch population, and the incidence of obesity as a significant risk factor for diabetes is increasing; and multiple screening initiatives are being implemented. Netherlands Diabetes Industry was valued at US$ 2.62 Billion in 2022.

According to the IDF, in 2019, 463 million people worldwide had diabetes, of whom approximately 1.1 million have type1. In the Netherlands, about 1.2 million people have diabetes, of which about 10% have type 1 diabetes. The factors that lead to type 1 diabetes can be both genetic and viral. In addition, the rise in the prevalence of weight gain also contributes to the increase in the disease.

Insulin Pen is predicted to grow at a significant rate during the Forecast Period

The Netherlands Market is segmented into Self Monitoring Blood Glucose Device, Continuous Glucose Monitoring Devices, Insulin Pumps, and Insulin Pens. The prevalence of diabetes is increasing among all ages in the Netherlands, primarily due to increase in overweight and obesity, unhealthy diet, and physical inactivity. Therefore, the demand and market for insulin pens are increasing in the Netherlands. The rise is due to the availability of reimbursement of insulin pens and an increase in the diabetic population.

Netherlands Diabetes Industry to expand at a CAGR of 4.23% from 2023 to 2028

The numbers of factors contributing to the high market share of insulin pumps in the Netherlands are as follows

  • The growing aging population

  • Increasing prevalence of diabetes

  • Rising awareness regarding the benefits of the insulin pump

  • High per capita disposable income

  • Advanced diabetes infrastructure

In addition, the gradual advancement of insulin pumps and their growing adoption among diabetes patients over conventional techniques are opening solid opportunities for the insulin pump market in the Netherlands.

Government Initiatives

The National Action program Diabetes (NAD) implementation in the Netherlands over the past decade has helped manage diabetes. It aims to inaugurate the Care Standard (CS) for diabetes using a particular implementation plan and to pilot it in several regions. For instance, Roche got CE Mark for its Accu-ChekSugarView app. Accu-ChekSugarView, the first app that examines blood glucose ranges by taking pictures with a Smartphone camera without requiring a blood glucose meter, in December 2019. Moreover, in 2018, The National Prevention Agreement was approved and set out ambitious goals to make the Netherlands healthier by 2040.

Key Players:

The Netherlands Diabetes Market comprises major manufacturers, B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (BD), Novo Nardisk, Ypsomed AG, Medtronic, Insulet Corporations, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care.

In May 2021, Medtronic secured European approvals for its Guardian 4 sensor. The Guardian 4 sensor can be either utilized as a standalone continuous glucose monitor or combined into Medtronic's insulin pumps and pens to add real-time glucose monitoring alongside insulin tracking.

Company Analysis

  • B. Braun Melsungen AG

  • Eli Lilly and Company

  • Terumo Corporation

  • Becton, Dickinson (BD)

  • Novo Nardisk

  • Ypsomed AG

  • Medtronic

  • Insulet Corporation

  • Abbott Laboratories

  • DarioHealth Crop

  • Dexcom, Inc

  • Roche Diagnostic

  • Tandem Diabetes Care

Report Metrics:

Report Attribute


No. of Pages


Forecast Period

2022 - 2028

Estimated Market Value (USD) in 2022

$2.62 Billion

Forecasted Market Value (USD) by 2028

$3.36 Billion

Compound Annual Growth Rate


Regions Covered


Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Netherlands Diabetes Market

6. Netherlands Diabetes Population
6.1 Type 1 Diabetes
6.2 Type 2 Diabetes

7. Market Share - Netherlands Diabetes Market
7.1 By Types

8. Continuous Glucose Monitoring Market (CGM) - Netherlands Market & Users
8.1 Netherlands - CGM Market by Components
8.1.1 Glucose Sensor Market & Forecast
8.1.2 CGM Transmitter Market & Forecast
8.2 Netherlands - CGM User
8.3 CGM Reimbursement in Netherlands

9. Blood Glucose Device (SMBG) - Netherlands Market & Users
9.1 Market
9.1.1 Type 1 Diabetes
9.1.2 Type 2 Diabetes
9.2 Test Strips Market
9.2.1 Type 1 Diabetes
9.2.2 Type 2 Diabetes
9.3 Lancet Market
9.3.1 Type 1 Diabetes
9.3.2 Type 2 Diabetes
9.4 Meter Market and Forecast
9.4.1 Type 1 Diabetes
9.4.2 Type 2 Diabetes
9.5 Blood Glucose (SMBG) Users
9.5.1 Type 1 Diabetes
9.5.2 Type 2 Diabetes
9.6 Reimbursement of Blood Glucose Devices inNetherlands

10. Insulin Pen - Netherlands Market & User
10.1 Insulin Pen Market
10.1.1 Disposable Insulin Pen Market
10.1.2 Reusable Insulin Pen Market
10.1.3 Smart Insulin Pen Market
10.2 Insulin Pen User
10.2.1 Disposable Insulin Pen User
10.2.2 Reusable Insulin Pen User
10.2.3 Smart Insulin Pen User
10.3 Insulin Pen Needle Market
10.4 Reimbursement Policies

11. Insulin Pump - Netherlands Market & Users
11.1 Insulin Pump Market
11.1.1 Type 1 Insulin Pump Market
11.1.2 Type 2 Insulin Pump Market
11.2 Insulin Pump User
11.2.1 Type 1 Insulin Pump User
11.2.2 Type 2 Insulin Pump User
11.3 Differentiation Points of Insulin Pump Products in Netherlands
11.3.1 Animas Vibe
11.3.2 Medtronic 530G with Enlite
11.3.3 InsuletOmniPod
11.3.4 Tandem t: slim
11.3.5 Roche Accu-Chek Combo
11.4 Training Model for Patients & HCP - of Medtronic, Animas, Insulet Corp & Tandem Diabetes Care
11.4.1 Medtronic
11.5 Insulet Corporation
11.5.1 Training Structure for New Patients - Insulet Corporation
11.6 Animas Corporation
11.6.1 Training Modules for New Patients
11.6.2 Training Modules for HCP (Health Care Professional)
11.7 Tandem Diabetes Care
11.8 Reimbursement Policies on Insulin Pump

12. Insulin Pen - Company Analysis

13. Insulin Pump - Company Analysis

14. SMBG - Company Analysis

15. CGM - Company Analysis

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


CONTACT: CONTACT: Laura Wood,Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900